

January 16, 2021

Dear Editor,

**Title : Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report**

**Author:** Lin Xiao, Lie Sun, Kang Zhao and Yi-Sheng Pan

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 59413

**(1) Reviewer's code: 01552044**

**Comments:** This is an interesting case report of potential interest to the readers of the Journal. The case is well presented, imaging is of good quality and I recommend this manuscript be accepted as is

**Authors' response:** Thank you very much for your valuable comment

**(2) Reviewer's code: 03544596**

**Comments:** Thanks to the authors for this case report. This agent is mostly used in the treatment of Crohn's disease. This case report is important as it reminds patients receiving Infliximab to closely monitor.

**Authors' response:** Thank you very much for your valuable comment

**(3) Reviewer's code: 04091933**

**Comments:** IBD and colorectal cancer with a worldwide increasing incidence and prevalence, are important gastroenterological pathologies that require special attention to patient management. Despite the fact that the therapeutic agents, including biologicals, are highly effective in the management of patients with IBD, the safety and long-term effects of biologic therapy are not fully understood. Infliximab has been used for over 20 years in clinical practice and is considered a relatively safe drug, although interference with the patient's immune system a priori can lead to serious infections and malignancies. The presented case of well-differentiated adenocarcinoma in a patient with IBD after infliximab therapy is interesting and clinically important, since it shows the possibility of rapid growth and progression of neoplasia, possibly induced by

biological therapy. This case can really increase the attention to the management of IBD patients with a focus on careful diagnosis and regular/continuous monitoring of patients on biologicals. The case is well described and illustrated and can be recommended for publication. References are relevant, fully consistent with the topic of the manuscript and without self-citation.

**Authors' response:** Thank you very much for your valuable comment

Thank you again for publishing our manuscript in the World Journal of Gastrointestinal Oncology

Sincerely yours,

Lin Xiao  
Department of general surgery,  
Peking University First Hospital,  
Xi ShiKu Street, Beijing, China.  
E-mail address: 15376732201@163.com